A5028649206- Glaucoma and retinal disorders
- Retinal Diseases and Treatments
- Bladder and Urothelial Cancer Treatments
- Retinal Imaging and Analysis
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Ocular Surface and Contact Lens
- Gynecological conditions and treatments
- Endometriosis Research and Treatment
- Uterine Myomas and Treatments
- Corneal surgery and disorders
- CAR-T cell therapy research
- Neurological Disorders and Treatments
- Ophthalmology and Visual Impairment Studies
- Retinal and Optic Conditions
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Atrial Fibrillation Management and Outcomes
- Genetics, Bioinformatics, and Biomedical Research
- Epigenetics and DNA Methylation
- Multiple Sclerosis Research Studies
- Retinal Development and Disorders
- Peripheral Artery Disease Management
- Viral Infectious Diseases and Gene Expression in Insects
Pfizer (United States)
2024-2025
Allergan (United States)
2016-2024
Taiwan Semiconductor Manufacturing Company (Taiwan)
2024
Seagen (Canada)
2024
AbbVie (United States)
2021-2022
Allergan (Ireland)
2021
AbbVie (Ireland)
2021
University of California, Los Angeles
2019
University of Washington
2015-2016
University of California, San Francisco
2014-2015
This post hoc analysis explores the relationship between early retinal anatomical response and long-term visual outcomes with ranibizumab in center-involved diabetic macular edema.Eyes randomized to plus prompt laser deferred treatment arms Protocol I study were categorized according their proportional reduction (<20 vs. ≥20%) central thickness (CRT) after 12 weeks. Adjusted unadjusted analyses assessed association (Week 12) (Weeks 52 156) best-corrected acuity outcomes.Of 335 eyes, 118...
Modeling of visual field and pharmacy data (Kaiser Permanente, 2001 to 2014) from open-angle/pseudoexfoliation glaucoma patients in clinical practice indicated a significant inverse association between the level medication adherence rate progression.The aim was quantify effect nonadherence topical hypotensive on glaucomatous progression practice.Retrospective analysis combined Kaiser Permanente Southern California's HealthConnect electronic health record database. Patients with diagnosis...
698 Background: Due to the evolving treatment landscape for muscle-invasive bladder cancer (MIBC), a better understanding of current patterns among real-world patients is needed. This study reported demographic and clinical characteristics examined with MIBC in US. Methods: non-interventional, retrospective cohort extracted data from Inovalon Insights Payer-Sourced dataset, claims database, January 1, 2020–December 31, 2021. Patients aged ≥18 years who were treated cystectomy or without...
To describe real-world patient characteristics, prior treatment patterns, and associated healthcare resource utilization (HRU) costs among patients with locally advanced/metastatic urothelial carcinoma (la/mUC) treated enfortumab vedotin (EV). This retrospective study used the United States (US) Centers for Medicare Medicaid Services 100% claims data from 2015 to 2020. Included had a diagnosis of la/mUC received EV. The index date was EV initiation date. Endpoints included HRU 12 months...
Abstract Background/objectives This post hoc analysis explores the relationship between residual oedema exposure after ranibizumab treatment initiation and long-term visual acuity outcome in eyes with centre-involved diabetic macular (DMO). Subjects/methods Eyes randomised to + prompt or deferred laser arms Protocol I trial observed central retinal thickness (CRT) readings at baseline ≥1 follow-up visits ( n = 367) were stratified by 1) duration (number of study CRT ≥ 250 µm during first 52...
PurposeTo assess anti-vascular endothelial growth factor (VEGF) management patterns and anatomic visual acuity (VA) outcomes among patients with neovascular age-related macular degeneration (nAMD) in United States clinical practice.DesignRetrospective observational cohort study.ParticipantsPatients (N = 30 106) initiating intravitreal anti-VEGF treatment for nAMD between October 2009 November 2016.MethodsAnalysis of longitudinal electronic health records from USRetina.Main Outcome...
To provide updated estimates of the clinical and economic burden in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) by disease severity United States to estimate incremental costs associated progression.Retrospective cohort study.Patients 1 more International Classification Diseases, 10th Revision, Clinical Modification, diagnoses for OAG OHT who are 40 years age older.Patients were identified from IQVIA's PharMetrics Plus database during index period (October 1, 2015,...
To determine the spectrum of glaucoma-associated health care resource utilization among outpatients attending National Health Service (NHS) hospital glaucoma clinics and costs managing in this setting. Retrospective observational cohort study using electronic medical record data. Patients aged ≥ 18 years 5 NHS United Kingdom (2013‒2018) with 12 months continuous Deidentified Medisoft Ophthalmology data (January 2013‒December 2018) from 43 742 eligible patients were categorized by year clinic...
Purpose . Two BRAF V600E targeted therapies, dabrafenib and vemurafenib, have received US approval for treatment of metastatic melanoma in patients, a mutation that affects ~50% patients. We evaluated the cost-effectiveness inhibitors traditional chemotherapy melanoma. Methods A Markov model was developed using societal perspective. Transition probabilities were derived from two Phase III registration trials comparing each inhibitor against dacarbazine. Costs obtained literature, national...
Precis: Incremental addition of intraocular pressure–lowering topical drops is associated with shorter-lasting benefit and higher health-related costs each additional agent, suggesting a need for new treatment options to improve disease control reduce burden. Purpose: The purpose this study was evaluate intensification as driver clinical economic burden in patients receiving glaucoma medications open-angle glaucoma/ocular hypertension. Methods: This retrospective analysis administrative...
BACKGROUND: Uterine fibroids (UF) affect up to 70%-80% of women by 50 years age and represent a substantial economic burden on patients society. Despite the high costs associated with UF, recent studies UF-related surgical treatments remain limited. OBJECTIVE: To describe health care resource utilization (HCRU) all-cause among diagnosed UF who underwent surgery. METHODS: Data from IBM MarketScan Commercial Claims Encounters database Medicaid Multi-State were independently, retrospectively...
Background/aims Topical agents to lower intraocular pressure (IOP) are the most common initial therapeutic measure in glaucoma prevention. This study aims assess treatment success duration among patients initiating or intensifying topical medication. Methods Medical records (2013‒2018) for adults initiating/intensifying medication were extracted from five secondary-care and tertiary-care UK ophthalmology centres. Main outcomes time initiation/intensification failure (<20% IOP reduction...
Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF.Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims Encounters Medicaid Multi-State databases. Women aged 18–64 years ≥1 inpatient or outpatient medical claim an initial UF diagnosis (index date) 1 January 2010 31 December 2014 included. Healthcare resource...
e16547 Background: Platinum-based chemotherapy (PBC) has been the standard of care for first-line (1L) locally advanced/metastatic urothelial carcinoma (la/mUC). This systematic literature review (SLR) and network meta-analysis (NMA) analyzed latest 1L clinical trial data to assess comparative efficacy novel regimen enfortumab vedotin in combination with pembrolizumab (EV+P) against PBC other approved investigational regimens patients la/mUC. Methods: English language publications...
PURPOSE Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, algorithms are increasingly used to define stage. To our knowledge, date, no study has algorithm categorize bladder (BC) (non–muscle-invasive BC [NMIBC], muscle-invasive [MIBC], or locally advanced/metastatic urothelial carcinoma [la/mUC]) in a US-based health care database. METHODS A was...
To estimate the healthcare resource utilization (HCRU) and costs for patients with normal tension glaucoma (NTG) as well their payers across various levels of disease severity.Our study was a retrospective cohort 6330 US NTG patients. Patients were enrolled if they 40 years or older had two more qualifying diagnoses within enrollment period, October 1st, 2015 to December 31st, 2017. Our analysis carried out cohorts - those unilateral bilateral disease. Baseline demographic clinical...